By: IPP Bureau
Last updated : November 24, 2025 1:11 pm
The company will soon be launching a new portfolio of products in this segment
Aptus Pharma Limited has announced its strategic entry into the Urology therapy segment as part of its ongoing business expansion initiatives.
The company will soon be launching a new portfolio of products in this segment, including: Silodosin range, Tamsulosin range and Alkalizer formulations.
The introduction of these products is supported by the Company's strong field-sales force and a robust distribution network consisting of 150+ PLS distributors and sub-distributors across India. This new portfolio is expected to contribute significantly to the Company's future revenue growth and profitability.
The Indian urology market is one of the fastest-growing chronic therapy segments, currently expanding at approximately 9-10% annually.
Commenting on this development, Tejash Hathi, Managing Director, Aptus Pharma Limited., stated: "Our entry into the urology therapy segment further strengthens our specialty-care capabilities and positions the Company for sustained growth in the coming years."